Hhdpharm Baricitinib Powder Material Baricitinib Anti-Rheumatism Baricitinib

Product Details
Customization: Available
Powder: Yes
Customized: Non-Customized
Diamond Member Since 2016

Suppliers with verified business licenses

Audited Supplier Audited Supplier

Audited by an independent third-party inspection agency

Importers and Exporters
The supplier has import and export rights
Full Customization
The supplier provides full customization services
ODM Services
The supplier provides ODM services
Quality Assurance
The supplier provides quality assurance
to see all verified strength labels (17)
  • Hhdpharm Baricitinib Powder Material Baricitinib Anti-Rheumatism Baricitinib
  • Hhdpharm Baricitinib Powder Material Baricitinib Anti-Rheumatism Baricitinib
  • Hhdpharm Baricitinib Powder Material Baricitinib Anti-Rheumatism Baricitinib
  • Hhdpharm Baricitinib Powder Material Baricitinib Anti-Rheumatism Baricitinib
  • Hhdpharm Baricitinib Powder Material Baricitinib Anti-Rheumatism Baricitinib
Find Similar Products

Basic Info.

Model NO.
Baricitinib
Suitable for
Adult
Purity
>98%
Color
White
Grade
Pharmaceutical Grade
Transport Package
Alumininum Foli Bags
Specification
10g, 50g, 200g, 1kg, 5kg
Trademark
hhdpharm
Origin
China

Product Description


Wuhan HHD Supply Pharmaceutical Baricitinib Powder Material Baricitinib Anti-Rheumatism Baricitinib 
 

Basic information:

Product Name Baricitinib 
Appearance White Powder
CAS No. 1187594-09-7 
MF C16H17N7O2S
Description:

Baricitinib, sold under the brand name Olumiant among others, is a drug for the treatment of rheumatoid arthritis (RA) in adults whose disease was not well controlled using RA medications called tumor necrosis factor (TNF) antagonists. It acts as an inhibitor of janus kinase (JAK), blocking the subtypes JAK1 and JAK2. The drug is approved for use in the European Union and the United States


Usage:
Baricitinib (baricitinib) obtained FDA emergency authorization (EUA) to be used in combination with Redecivir to treat patients who require supplemental oxygen, intubation ventilation or extracorporeal membrane oxygenation, children over 2 years of age, or adult hospitalized patients with new coronary pneumonia or Suspected patient. The FDA emergency authorization is based on a clinical trial (ACTT-2) conducted by the National Institute of Allergy and Infectious Diseases (ACTT-2). Compared with radcivir monotherapy, baritinib is combined with radcivir. It can reduce the patient's recovery time during the 29-day treatment period.
 

Hhdpharm Baricitinib Powder Material Baricitinib Anti-Rheumatism BaricitinibHhdpharm Baricitinib Powder Material Baricitinib Anti-Rheumatism BaricitinibHhdpharm Baricitinib Powder Material Baricitinib Anti-Rheumatism BaricitinibHhdpharm Baricitinib Powder Material Baricitinib Anti-Rheumatism BaricitinibHhdpharm Baricitinib Powder Material Baricitinib Anti-Rheumatism BaricitinibHhdpharm Baricitinib Powder Material Baricitinib Anti-Rheumatism BaricitinibHhdpharm Baricitinib Powder Material Baricitinib Anti-Rheumatism Baricitinib

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now
Contact Supplier